Literature DB >> 25981602

Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets.

Sae Hasegawa, Mayu Kasubuchi, Kazuya Terasawa, Ikuo Kimura1.   

Abstract

Progesterone receptor membrane components 1 and 2, neudesin, and neuferricin belong to the membraneassociated progesterone receptor (MAPR) family. Recently, sex steroid membrane receptors have gained attention because of their potential involvement in sex hormone-mediated rapid non-genomic effects, which cannot currently be explained by the genomic action of nuclear receptors. Progesterone may increase cell proliferation and survival via nongenomic effects including the activation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3- kinase (PI3K) pathways through MAPRs. Moreover, the unique expression of MAPRs suggests that they could be used as biomarkers and drug targets for sex steroid-related cancers and other diseases. In this review, we summarize the physiological roles of the MAPRs, provide a comprehensive overview of their progesterone-mediated non-genomic actions, and discuss new insights into their potential as therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25981602     DOI: 10.2174/1389450116666150518102651

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  3 in total

Review 1.  Membrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions - Focus on Interactions with Cytochromes P450.

Authors:  Chang S Ryu; Kathrin Klein; Ulrich M Zanger
Journal:  Front Pharmacol       Date:  2017-03-27       Impact factor: 5.810

Review 2.  Molecular Characterization of Membrane Steroid Receptors in Hormone-Sensitive Cancers.

Authors:  Mirco Masi; Marco Racchi; Cristina Travelli; Emanuela Corsini; Erica Buoso
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

3.  Expression of CYB5D2 is associated with epithelial-mesenchymal transition and survival rates in patients with cervical cancer.

Authors:  Dongxue Li; Bing Qiu; Xiaohang Chen; Liang Hu; Lijuan Wen; Fengxiang Wei
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.